NasdaqCM - Delayed Quote USD

China SXT Pharmaceuticals, Inc. (SXTC)

Compare
0.4693
-0.0087
(-1.82%)
At close: January 10 at 4:00:00 PM EST
0.4500
-0.02
(-4.11%)
After hours: January 10 at 5:43:13 PM EST
Currency in USD All numbers in thousands
Download
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
1,928.4970
1,928.4970
1,971.6790
2,602.2810
4,777.5730
Cost of Revenue
1,374.5260
1,374.5260
1,545.4080
1,350.6380
1,938.0230
Gross Profit
553.9710
553.9710
426.2710
1,251.6430
2,839.5500
Operating Expense
3,069.1880
3,069.1880
6,033.7800
6,441.3160
5,036.6260
Operating Income
-2,515.2170
-2,515.2170
-5,607.5090
-5,189.6730
-2,197.0760
Net Non Operating Interest Income Expense
-544.2790
-544.2790
-476.7760
-36.6950
-1,615.4400
Other Income Expense
-39.0360
-39.0360
149.5130
-181.5810
871.6500
Pretax Income
-3,098.5320
-3,098.5320
-5,934.7720
-5,407.9490
-2,940.8660
Tax Provision
--
--
--
328.1460
-192.6830
Net Income Common Stockholders
-3,098.5320
-3,098.5320
-5,934.7720
-5,736.0950
-2,748.1830
Diluted NI Available to Com Stockholders
-3,098.5320
-3,098.5320
-5,934.7720
-5,736.0950
-2,748.1830
Basic EPS
-26.95
-3.57
-22.23
-137.92
-95.47
Diluted EPS
-26.95
-3.57
-22.23
-137.92
-95.47
Basic Average Shares
466.5480
867.4220
266.9730
41.5910
28.7810
Diluted Average Shares
466.5480
867.4220
266.9730
41.5910
28.7810
Total Operating Income as Reported
-2,515.2170
-2,515.2170
-5,607.5090
-5,189.6730
-2,197.0760
Total Expenses
4,443.7140
4,443.7140
7,579.1880
7,791.9540
6,974.6490
Net Income from Continuing & Discontinued Operation
-3,098.5320
-3,098.5320
-5,934.7720
-5,736.0950
-2,748.1830
Normalized Income
-3,098.5320
-3,098.5320
-5,934.7720
-5,736.0950
-2,748.1830
Interest Expense
544.2790
544.2790
476.7760
36.6950
--
Net Interest Income
-544.2790
-544.2790
-476.7760
-36.6950
-1,615.4400
EBIT
-2,554.2530
-2,554.2530
-5,457.9960
-5,371.2540
-2,197.0760
EBITDA
-2,351.0060
-2,351.0060
-5,207.8340
-5,051.2470
-1,851.6620
Reconciled Cost of Revenue
1,374.5260
1,374.5260
1,545.4080
1,350.6380
1,938.0230
Reconciled Depreciation
203.2470
203.2470
250.1620
320.0070
345.4140
Net Income from Continuing Operation Net Minority Interest
-3,098.5320
-3,098.5320
-5,934.7720
-5,736.0950
-2,748.1830
Normalized EBITDA
-2,351.0060
-2,351.0060
-5,207.8340
-5,051.2470
-1,851.6620
Tax Rate for Calcs
--
--
--
0.0003
0.0001
3/31/2021 - 1/4/2019

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

YCBD cbdMD, Inc.
0.5630
+13.28%
 
CPHI China Pharma Holdings, Inc.
0.2199
+4.17%
 
PTPI Petros Pharmaceuticals, Inc.
0.3761
+3.32%
 
BFRI Biofrontera Inc.
1.1200
-5.08%
 
GHSI Guardion Health Sciences, Inc.
3.2200
0.00%
 
AKAN Akanda Corp.
1.5600
-3.11%
 
ZYBT Zhengye Biotechnology Holding Limited
4.6162
+2.58%
 
UPC Universe Pharmaceuticals INC
0.6299
+1.93%
 
SBFM Sunshine Biopharma, Inc.
2.9300
-1.35%
 
PRFX PainReform Ltd.
3.1500
-0.63%